Last reviewed · How we verify
GR1801
GR1801 is an investigational therapeutic in phase 3 development by Genrix Biopharmaceutical, but its specific mechanism of action is not publicly disclosed.
At a glance
| Generic name | GR1801 |
|---|---|
| Sponsor | Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Without access to detailed clinical trial data or company disclosures, the precise molecular target and mechanism cannot be reliably determined. Phase 3 status indicates the drug has shown sufficient efficacy and safety in earlier trials to warrant late-stage clinical evaluation.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |